mb-102
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Mustang BioPhase 1/2Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 89/ 100
Competitive context
35 Active assets in the Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tagraxofusp French Innovative Leukemia Organisation | Phase 2 | BB |
Cyclophosphamide Fred Hutchinson Cancer Center | Phase 2 | BB |
Fludarabine Fred Hutchinson Cancer Center | Phase 2 | BB |
METHOTREXATE Therapeutic Advances in Childhood Leukemia Consortium | Phase 2 | BB |
Fludarabine Therapeutic Advances in Childhood Leukemia Consortium | Phase 2 | B |
View all 48 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →